Targeting the BCR pathway has emerged as a promising therapeutic strategy for B-cell lymphomas, with BTK inhibitors at the forefront of this approach (Wang et al., 2021). This evidence concerns the gene BTK and B-cell non-Hodgkin lymphoma.